Arcus Biosciences, a clinical-stage biotech developing cancer immunotherapies, raised $120 million by offering 8 million shares at $15, the high end of the range of $13 to $15. Arcus Biosciences plans to list on the NYSE under the symbol RCUS. Citi, Goldman...read more
The IPO market is back in session. The first unicorn of the year, Zscaler (ZS), headlines the week ahead featuring four companies that are targeting a combined $386 million. A strong debut could nudge forward a number of other software...read more
Arcus Biosciences, a clinical-stage biotech developing cancer immunotherapies, announced terms for its IPO on Monday. The Hayward, CA-based company plans to raise $99 million by offering 7.1 million shares at a price range of $13 to $15. At the midpoint of...read more
US IPO Weekly Recap: Tech unicorn Zscaler pops 100%, Dropbox and Spotify up next
As expected, the year's first unicorn was a winner. Cybersecurity provider...read more
Arcus Biosciences prices upsized IPO at $15 high end
Arcus Biosciences, a clinical-stage biotech developing cancer immunotherapies, raised $120 million by offering 8 million shares at $15, the high end of the range of $13 to $15. Arcus Biosciences plans to list on the NYSE under the symbol RCUS. Citi, Goldman...read more
US IPO Week Ahead: Year's first unicorn leads a pickup in activity with 4 IPOs
The IPO market is back in session. The first unicorn of the year, Zscaler (ZS), headlines the week ahead featuring four companies that are targeting a combined $386 million. A strong debut could nudge forward a number of other software...read more
Immuno-oncology biotech Arcus Biosciences sets terms for $99 million IPO
Arcus Biosciences, a clinical-stage biotech developing cancer immunotherapies, announced terms for its IPO on Monday. The Hayward, CA-based company plans to raise $99 million by offering 7.1 million shares at a price range of $13 to $15. At the midpoint of...read more